90
Participants
Start Date
September 27, 2012
Primary Completion Date
April 24, 2019
Study Completion Date
April 24, 2019
Gemcitabine and Pazopanib
Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.
Gemcitabine and Docetaxel
Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
Johns Hopkins University, Baltimore
Emory University, Atlanta
University of Michigan, Ann Arbor
Washington University at St. Louis, St Louis
University of Texas MD Anderson Cancer Center, Houston
University of Colorado Cancer Center, Aurora
The University of Arizona Cancer Center, Tucson
University of Iowa Hospitals & Clinics, Iowa City
Collaborators (1)
Novartis
INDUSTRY
Medical University of South Carolina
OTHER